JPH10120558A - Skin preparation for improving sputum for external use - Google Patents

Skin preparation for improving sputum for external use

Info

Publication number
JPH10120558A
JPH10120558A JP27665896A JP27665896A JPH10120558A JP H10120558 A JPH10120558 A JP H10120558A JP 27665896 A JP27665896 A JP 27665896A JP 27665896 A JP27665896 A JP 27665896A JP H10120558 A JPH10120558 A JP H10120558A
Authority
JP
Japan
Prior art keywords
group
action
skin
treatment
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP27665896A
Other languages
Japanese (ja)
Inventor
Masanori Kosuge
正規 小菅
Takuo Kosuge
卓夫 小菅
Nobuhiro Ando
信裕 安藤
Yoshie Muramatsu
宜江 村松
Mitsuo Kawai
充夫 河合
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOKUTAAZU KOSUMETEIKUSU KK
Pola Chemical Industries Inc
Original Assignee
DOKUTAAZU KOSUMETEIKUSU KK
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOKUTAAZU KOSUMETEIKUSU KK, Pola Chemical Industries Inc filed Critical DOKUTAAZU KOSUMETEIKUSU KK
Priority to JP27665896A priority Critical patent/JPH10120558A/en
Publication of JPH10120558A publication Critical patent/JPH10120558A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain the subject skin preparation containing a compound such as capsaicin, sinapine or curcumine and capable of improving the action of sputum. SOLUTION: The skin preparation contains a compound of the formula (R1 and R3 are each a short chain length acyloxy, a short chain length alkyloxy, OH, H; R2 is an acyloxy, OH; R4 is a carbonylalkenyl or alkenylcarbonyl which may have N or an aromatic group) in an amount of 0.001-10wt.% as an active ingredient. The compound of the formula has a beautifully skin-whitening action, actions for treating dermatitis such as atopic dermatitis, eczema, dermatomycosis, verruca, dyspigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma and burn, a hair growth-stimulating action, a perspiration- stimulating action, a digestive juice secretion-stimulating action, a diuretic action, a dejection-stimulating action, etc. These actions are exhibited by the percutaneous administration of the preparation.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、津液作用の改善に
有益な化粧料、医薬等の皮膚外用剤に関する。
TECHNICAL FIELD The present invention relates to an external preparation for skin such as cosmetics and medicines, which is useful for improving the action of tsukusu.

【0002】[0002]

【従来の技術】漢方思想における気、血、水の考え方
は、その薬理作用の捉え方のユニークさと、漢方薬選択
時の合理的な指標であるために、古くより研究されてき
た。これらの内、気、血の意味するものについては、多
くのことが解明されてきた。例えば、血とは酸素、栄養
等エネルギーを中心とする補給・代謝を表すキーワード
であり、気とは生命活動の恒常性機構の活動状況と生命
活動の原動力の状況を表すキーワードであることが知ら
れている。
2. Description of the Related Art The concept of qi, blood, and water in Chinese medicine has long been studied because of its uniqueness in understanding its pharmacological action and a rational index for selecting Chinese medicine. Of these, many have been elucidated about the meanings of qi and blood. For example, it is known that blood is a keyword that represents the supply and metabolism mainly of energy such as oxygen and nutrition, and ki is a keyword that represents the status of the homeostasis of life activity and the status of the driving force of life activity. Have been.

【0003】しかし、水(津液)の働きについては老廃
物の代謝・排泄作用のみしか知られておらず、気・血・
水の論理体型において遅れて認識された為、その真の作
用(津液作用)の解明は未完であった。また、津液作用
と現代医学で認識されている種々の薬理作用等との関係
や津液の現代医学における役割などはあまり知られてお
らず、現代医学の分野における津液作用の解明及び津液
作用の改善をもたらす化粧料、医薬等の開発が望まれて
いた。
[0003] However, only the metabolism and excretion of waste products is known for the function of water (tsu liquor).
Since the recognition was delayed in the logical form of water, the elucidation of its true action (Tsukumi action) was incomplete. Also, little is known about the relationship between the pulp action and the various pharmacological actions recognized in modern medicine, and the role of pulp in modern medicine. The development of cosmetics, medicines, etc. that bring about such problems has been desired.

【0004】[0004]

【発明が解決しようとする課題】本発明はこのような状
況を踏まえてなされたものであり、津液の真の作用を明
らかにし、津液作用の改善に用いられる皮膚外用剤を提
供することを課題とする。
DISCLOSURE OF THE INVENTION The present invention has been made in view of such circumstances, and has as its object to clarify the true function of a tsuju and to provide an external preparation for skin used to improve the action of a tsuku. And

【0005】[0005]

【課題を解決するための手段】本発明者等は、このよう
な状況に鑑み、津液の真の作用を求めて鋭意研究を重ね
た結果、津液作用が、ある種の物質の働きによって水分
の体外への分泌を司る器官を刺激し、体内水分の体外へ
の分泌を促進させる作用を意味していることを見いだし
た。そして、そのような分泌器官を刺激し津液作用を促
進・改善しうる物質について検討した結果、本発明を完
成した。
Means for Solving the Problems In view of such a situation, the present inventors have conducted intensive studies in search of the true function of tsuju. It was found that it stimulates the organs responsible for extracorporeal secretion and promotes the secretion of body water out of the body. Then, as a result of examining substances capable of stimulating such secretory organs and promoting / improving the action of the pulp, the present invention was completed.

【0006】すなわち、本発明は、下記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる1種又は2種以上を有効成分とする津液
改善用皮膚外用剤を提供するものである。
[0006] That is, the present invention provides a skin for improving a tsunami containing one or more active ingredients selected from the group consisting of a compound represented by the following general formula (I) and a physiologically acceptable salt thereof. It provides an external preparation.

【0007】[0007]

【化5】 Embedded image

【0008】[式(I)中、R1、R3はそれぞれ独立に
低鎖長アルキル基、低鎖長アルキルオキシ基、水酸基又
は水素原子を表し、R2はアシルオキシ基又は水酸基を
表し、R4は窒素原子又は芳香族基を有していてもよい
カルボニルアルケニル基もしくはアルケニルカルボニル
基を表す。]
In the formula (I), R 1 and R 3 each independently represent a low-chain alkyl group, a low-chain alkyloxy group, a hydroxyl group or a hydrogen atom; R 2 represents an acyloxy group or a hydroxyl group; 4 represents a nitrogen atom or a carbonylalkenyl group or an alkenylcarbonyl group which may have an aromatic group. ]

【0009】本発明者らは、津液作用が、真皮から表皮
への水分分泌を促進し表皮に十分な水分を保持させるこ
とによって起こる美肌作用、アトピー性皮膚炎、湿疹、
皮膚真菌症、疣贅、色素沈着症、尋常性乾癬、老人性乾
皮症、老人性角化腫、火傷等の各種皮膚疾患治療作用、
発毛促進作用、発汗促進作用、胃壁、腎臓、腸管での水
分分泌を促進させることによって起こる消化液分泌促進
作用、利尿作用、便通促進作用にかかわる作用であるこ
とを見出した。
[0009] The present inventors have found that the tsuyu action promotes the secretion of water from the dermis to the epidermis and causes the epidermis to retain sufficient moisture, resulting in a beautiful skin action, atopic dermatitis, eczema,
Dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma, therapeutic effects on various skin diseases such as burns,
It has been found that the action is related to a hair growth promoting action, a sweat promoting action, a digestive juice secretion promoting action, a diuretic action and a bowel movement promoting action caused by promoting water secretion in the stomach wall, kidney and intestinal tract.

【0010】すなわち、漢方生薬の薬効分類を詳細に検
討し、現代医薬分類との対比を行った結果、水(津液)
が関与すると言われている、しゃ下、利水、消導、補陰
と言った薬草群の作用が現代医薬品分類における美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、利尿作用、便通促進作用と係わ
りが深いことを見いだした。
That is, the medicinal classification of Chinese herbal medicines was examined in detail, and compared with modern medicine classifications.
It is said that the effects of the herbs such as shampoo, irrigation, conduction and prosthesis are related to beautiful skin effect, atopic dermatitis treatment, and dermatitis group treatment represented by eczema in the modern pharmaceutical classification. , Dermatomycosis treatment, wart treatment, pigmentation such as hepatitis, psoriasis vulgaris, senile xeroderma, senile keratoma treatment, skin damage treatment due to physical causes It has been found that it is closely related to the action, the hair growth promoting action, the digestive juice secretion promoting action, the sweating promoting action, the diuretic action and the bowel movement promoting action.

【0011】この知見をもとに種々の物質について美肌
作用、アトピー性皮膚炎治療作用、発毛促進作用、湿疹
の治療作用、消化液分泌促進作用、発汗促進作用を指標
にスクリーニングを重ねたところ、上記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる化合物がこのような作用に優れることを
見いだした。更に驚くべきことに、上記一般式(I)で
表される化合物及びその生理的に許容される塩からなる
群から選ばれる化合物を外用投与することにより、胃酸
等の消化液の分泌が促されるなどの効果があることを見
出し、本発明を完成させるに至った。
Based on this finding, screening was carried out on various substances based on the indicators of skin beautiful action, atopic dermatitis treatment action, hair growth promotion action, eczema treatment action, digestive juice secretion promotion action and sweating promotion action. It has been found that a compound selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof is excellent in such action. Even more surprisingly, by externally administering a compound selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof, secretion of digestive juice such as stomach acid is promoted. The present inventors have found that the present invention has such effects as described above, and have completed the present invention.

【0012】上記一般式(I)で表される化合物又はそ
の生理的に許容される塩が経皮吸収促進作用、肝機能の
改善や免疫機能の改善作用を有していることは知られて
いるものの、真の意味での津液改善作用があることは知
る余地もなかった。更に、上記一般式(I)で表される
化合物又はその生理的に許容される塩が美肌作用、アト
ピー性皮膚炎、湿疹、皮膚真菌症、疣贅、色素沈着症、
尋常性乾癬、老人性乾皮症、老人性角化腫、火傷等の皮
膚疾患治療作用、発毛促進作用、発汗促進作用、消化液
分泌促進作用、利尿作用、便通促進作用を有することは
全く知られていなかった。
It is known that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof has a percutaneous absorption promoting action, a liver function improving action and an immune function improving action. However, there was no way to know that there was a true improvement of the tsuyu. Further, the compound represented by the above general formula (I) or a physiologically acceptable salt thereof may be used as a beautifying agent, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation,
It has no action to treat skin diseases such as psoriasis vulgaris, senile xeroderma, senile keratoma, burns, etc., hair growth promoting action, sweat sweat promoting action, digestive juice secretion promoting action, diuretic action, and bowel movement promoting action. Was not known.

【0013】[0013]

【発明の実施の形態】以下に、本発明の実施の形態を説
明する。本発明の津液改善用皮膚外用剤は、上記一般式
(I)で表される化合物及びその生理的に許容される塩
からなる群から選ばれる1種又は2種以上を有効成分と
する。
Embodiments of the present invention will be described below. The skin external preparation for tsumuage improvement of the present invention contains, as an active ingredient, one or more selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof.

【0014】ここで、式(I)中、R1、R3はそれぞれ
独立に低鎖長アルキル基、低鎖長アルキルオキシ基、水
酸基又は水素原子を表し、R2はアシルオキシ基又は水
酸基を表し、R4は窒素原子又は芳香族基を有していて
もよいカルボニルアルケニル基もしくはアルケニルカル
ボニル基を表す。ここでいう低鎖長とは、好ましくは炭
素数1〜4の直鎖又は分岐の炭素鎖である。また、カル
ボニルアルケニル基もしくはアルケニルカルボニル基と
は、好ましくは炭素数3〜10のアルケニル基を有する
ものである。本発明においては、R1及びR3はそれぞれ
独立に水酸基又はメトキシ基であることが好ましい。ま
た、R2は水酸基であることが好ましい。
In the formula (I), R 1 and R 3 each independently represent a low-chain alkyl group, a low-chain alkyloxy group, a hydroxyl group or a hydrogen atom, and R 2 represents an acyloxy group or a hydroxyl group. And R 4 represent a nitrogen atom or a carbonylalkenyl group or an alkenylcarbonyl group which may have an aromatic group. Here, the low chain length is preferably a straight or branched carbon chain having 1 to 4 carbon atoms. Further, the carbonylalkenyl group or the alkenylcarbonyl group preferably has an alkenyl group having 3 to 10 carbon atoms. In the present invention, R 1 and R 3 are preferably each independently a hydroxyl group or a methoxy group. Further, R 2 is preferably a hydroxyl group.

【0015】一般式(I)で表される化合物としては、
カプサイシン、シナピン、クルクミン、イソフェレイリ
ン、7−O−エチルイソフェレイリン、レスペデオール
C、イソサチバノン、ネオウラレノール、6−メトキシ
カプサイシン等が例示できこれらがいずれも使用でき
る。これらの内好ましいものは、下記一般式(II)で
表されるカプサイシン、下記一般式(III)で表され
るシナピン、及び下記一般式(IV)で表されるクルク
ミン、並びにこれらの水酸基のアシル化物である。
The compound represented by the general formula (I) includes
Examples thereof include capsaicin, sinapine, curcumin, isofelelin, 7-O-ethylisoferrein, respedole C, isosatibanone, neouralenol, and 6-methoxycapsaicin, and any of these can be used. Of these, preferred are capsaicin represented by the following general formula (II), sinapine represented by the following general formula (III), curcumin represented by the following general formula (IV), and acyls of these hydroxyl groups Is a monster.

【0016】[0016]

【化6】 Embedded image

【0017】[0017]

【化7】 Embedded image

【0018】[0018]

【化8】 Embedded image

【0019】アシル化物におけるアシル基としては、炭
素数1〜4の低鎖長のものが好ましく、例えば、アセチ
ル基等が好ましく例示できる。かかるアシル化物は、例
えば、アルカリ存在下、酸に塩化チオニル等を作用させ
て得たアシルクロライドを作用させれば容易に得られ
る。又、アルカリ存在下酸無水物を反応させてもよい。
以下にアシル化物の製造例を挙げる。
The acyl group in the acylated product is preferably an acyl group having a low chain length of 1 to 4 carbon atoms, such as an acetyl group. Such an acylated product can be easily obtained, for example, by reacting an acid with an acyl chloride obtained by reacting thionyl chloride or the like with an acid in the presence of an alkali. Further, an acid anhydride may be reacted in the presence of an alkali.
Hereinafter, production examples of the acylated product will be described.

【0020】[製造例1]カプサイシン1gをピリジン
100mlに溶かし、氷冷下無水酢酸100mlを滴下
し、室温で24時間撹拌した後、濃縮しシリカゲルカラ
ムクロマトグラフィーで精製し、定量的にアセチルカプ
サイシンを得る。
[Preparation Example 1] 1 g of capsaicin was dissolved in 100 ml of pyridine, 100 ml of acetic anhydride was added dropwise under ice cooling, and the mixture was stirred at room temperature for 24 hours, concentrated, purified by silica gel column chromatography, and quantitatively purified with acetylcapsaicin. obtain.

【0021】[製造例2]シナピン1gをピリジン10
0mlに溶かし、氷冷下無水酢酸100mlを滴下し、
室温で24時間撹拌した後、濃縮しシリカゲルカラムク
ロマトグラフィーで精製し、定量的にアセチルシナピン
を得る。
[Production Example 2] 1 g of sinapine was added to pyridine 10
0 ml, and 100 ml of acetic anhydride was added dropwise under ice cooling.
After stirring at room temperature for 24 hours, the mixture is concentrated and purified by silica gel column chromatography to quantitatively obtain acetylsinapine.

【0022】[製造例3]クルクミン1gをピリジン1
00mlに溶かし、氷冷下無水酢酸100mlを滴下
し、室温で24時間撹拌した後、濃縮しシリカゲルカラ
ムクロマトグラフィーで精製し、定量的にアセチルクル
クミンを得る。
[Production Example 3] 1 g of curcumin was added to 1 of pyridine
After dissolving in 100 ml, 100 ml of acetic anhydride was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 24 hours, concentrated, and purified by silica gel column chromatography to quantitatively obtain acetylcurcumin.

【0023】また、上記一般式(I)で表される化合物
の生理的に許容される塩とは、例えば、ナトリウム、カ
リウム等のアルカリ金属塩、カルシウム、マグネシウム
等のアルカリ土類金属塩、アンモニウム塩、トリエチル
アミンやトリエタノールアミン等の有機アミン塩、リジ
ンやアルギニン等の塩基性アミノ酸塩等が好ましく例示
できる。これらの対塩基は1種でも2種以上を組み合わ
せて用いても構わない。
The physiologically acceptable salts of the compounds represented by the above general formula (I) include, for example, alkali metal salts such as sodium and potassium, alkaline earth metal salts such as calcium and magnesium, and ammonium. Preferred examples thereof include salts, organic amine salts such as triethylamine and triethanolamine, and basic amino acid salts such as lysine and arginine. These counterbases may be used alone or in combination of two or more.

【0024】一般式(I)で表される化合物及び/又は
その生理的に許容される塩はいずれも市販されており入
手可能である。本発明の皮膚外用剤としては、基礎化粧
料やメークアップ化粧料、頭髪用化粧料、浴用剤などの
化粧料や、抗炎症外用剤等の皮膚外用医薬組成物が例示
できる。本発明の皮膚外用剤における上記一般式(I)
で表される化合物又はその生理的に許容される塩の好ま
しい含有量は、皮膚外用剤全体に対し0.001〜10
重量%であり、より好ましくは0.01〜10重量%で
あり、更に好ましくは0.01〜5重量%である。
The compound represented by the general formula (I) and / or a physiologically acceptable salt thereof are all commercially available. Examples of the external preparation for skin of the present invention include cosmetics such as basic cosmetics, make-up cosmetics, hair cosmetics, bath preparations and the like, and skin external pharmaceutical compositions such as anti-inflammatory external preparations. Formula (I) in the external preparation for skin of the present invention
The preferred content of the compound represented by or a physiologically acceptable salt thereof is 0.001 to 10
%, More preferably 0.01 to 10% by weight, even more preferably 0.01 to 5% by weight.

【0025】本発明の皮膚外用剤は、上記一般式(I)
で表される化合物又はその生理的に許容される塩以外
に、化粧料、皮膚外用医薬組成物等で通常用いられてい
る任意成分を含有することができる。このような任意成
分としては、ワセリンやマイクロクリスタリンワックス
等のような炭化水素類、ホホバ油やゲイロウ等のエステ
ル類、牛脂、オリーブ油等のトリグリセライド類、セタ
ノール、オレイルアルコール等の高級アルコール類、ス
テアリン酸、オレイン酸等の脂肪酸、グリセリンや1,
3−ブタンジオール等の多価アルコール類、非イオン界
面活性剤、アニオン界面活性剤、カチオン界面活性剤、
両性界面活性剤、エタノール、カーボポール等の増粘
剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類等
が例示できる。これらの任意成分と上記一般式(I)で
表される化合物又はその生理的に許容される塩とを常法
に従って処理することにより、本発明の皮膚外用剤を製
造することができる。
The external preparation for skin of the present invention has the above general formula (I)
In addition to the compound represented by the formula (I) or a physiologically acceptable salt thereof, the composition may contain optional components commonly used in cosmetics, skin external pharmaceutical compositions and the like. Such optional components include hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, higher alcohols such as cetanol and oleyl alcohol, and stearic acid. , Fatty acids such as oleic acid, glycerin and 1,
Polyhydric alcohols such as 3-butanediol, nonionic surfactants, anionic surfactants, cationic surfactants,
Examples include amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, pigments, and powders. The external preparation for skin of the present invention can be produced by treating these optional components with the compound represented by the above general formula (I) or a physiologically acceptable salt thereof in a conventional manner.

【0026】本発明の津液改善用皮膚外用剤は、津液作
用の促進・改善に用いられる。津液作用は、その発現形
態としてしゃ下作用、利水作用、補陰作用、消導作用と
して生体に発現することが知られている。これらの作用
を有する漢方生薬としては、しゃ下作用であれば、ダイ
オウ、バンシャヨウ、ロカイ、マシニン、ケンゴシ、カ
ンスイ、ゲンカ、ゾクズイシ、ウキュウコンピ等が知ら
れており、利水作用を有する漢方生薬としては、チョレ
イ、ブクリョウ、タクシャ、インチンコウ、ヨクイニ
ン、トウカニン、ジフシ、トウキヒ、キンセンソウ等が
知られており、補陰作用を有する漢方生薬としては、シ
ャジン、セイヨウジン、テンモンドウ、バクモンドウ、
セッコク、ギョクチク、ヒャクゴウ、ソウキセイ、カン
レンソウ、ジョテイシ、ゴマ、コクズ、キバン、ベッコ
ウ等が知られており、消導作用を有する漢方生薬として
は、サンザシ、クレンコンピ、ヒシ、カクシツ、ライガ
ン、ビンロウジ、ナンカシ、タイサン等が知られてい
る。
The skin external preparation for improving tidal fluid of the present invention is used for promoting / improving the action of liquor. It is known that the tsuju action is expressed in a living body as a mode of expression, such as a shampooing action, a water-supplying action, a prosthesis action, and a conduction action. As a herbal crude drug having these effects, if it is a shampooing effect, rhubarb, banshayou, rokai, machinin, kengoshi, Kansui, Genka, Zokuzuishi, kyukyu compi, etc. Chorei, Bukuryo, Taksha, Inchinko, Jokuinin, Toukanin, Difushi, Tokhihi, Kinsenso and the like are known, and as herbal crude drugs having a prosthetic effect, Shajin, Eurasia, Tenmondou, Bakumondou,
Ginseng, arctic, antelope, sycamore, renren, jotenishi, sesame, kokuzu, kiban, bekko are known, and as a herbal crude drug having an antidepressant effect, hawthorn, krenkonpi, hishi, kakushitsu, reigan, areca, nankashi, Taisan and the like are known.

【0027】これらについての文献等を調べてみると、
美肌作用、発毛促進作用、抗アレルギー作用、抗炎症作
用、消化促進作用等の薬理作用が重複していることが見
出された。ここに本発明者等は注目し、「水」(津液)
の作用は現代医学における美肌作用、アトピー性皮膚
炎、湿疹、皮膚真菌症、疣贅、色素沈着症、尋常性乾
癬、老人性乾皮症、老人性角化腫、火傷等の皮膚疾患の
治療作用、発毛促進作用、吹き出物の治療作用、消化液
分泌促進作用、発汗促進作用、利尿作用、便通促進作用
等を指標とすることができることを見出した。尚、これ
らの作用の一つを有する物質は、大なり小なり他の作用
も有している場合が多い。したがって、これらの作用の
一つを指標にするスクリーニングを行えば、他の作用の
推定を行うこともできる。
Examining the literature and the like about these,
It has been found that pharmacological actions such as beautifying action, hair growth-promoting action, anti-allergic action, anti-inflammatory action, and digestion promoting action overlap. Here, the present inventors pay attention, and consider "water" (Tsu liquid).
Works in modern medicine to treat skin disorders such as skin beautification, atopic dermatitis, eczema, dermatomycosis, warts, pigmentation, psoriasis vulgaris, senile xeroderma, senile keratoma and burns It has been found that the action, the hair growth promoting action, the therapeutic action of pimples, the digestive juice secretion promoting action, the sweat promoting action, the diuretic action, the bowel movement promoting action and the like can be used as indices. In addition, substances having one of these actions often have other actions to a greater or lesser degree. Therefore, if screening is performed using one of these actions as an index, other actions can be estimated.

【0028】本発明の津液改善用皮膚外用剤は、美肌作
用、アトピー性皮膚炎治療作用、湿疹で代表される皮膚
炎群治療作用、皮膚真菌症治療作用、疣贅治療作用、肝
炎で代表される色素沈着症治療作用、尋常性乾癬治療
症、老人性乾皮症、老人性角化腫治療作用、物理的原因
による皮膚損傷治療作用、発毛促進作用、消化液分泌促
進作用、発汗促進作用、便通促進作用、及び排尿促進
(利尿)作用からなる群から選ばれる少なくとも一つを
改善する作用を有しており、これを用いることにより、
肌の衰えの防止と改善、アトピー性皮膚炎の治療と発症
・悪化の防止、発毛の促進と抜け毛の予防、湿疹の改善
と悪化の予防、便通の促進と排尿の促進等の効果が発揮
される。
The topical skin preparation for improving tanning solution of the present invention is represented by a skin beautifying effect, an atopic dermatitis treating effect, a dermatitis group represented by eczema, a dermatomycosis treating effect, a wart treating effect, and hepatitis. Therapeutic action for pigmentation disease, psoriasis vulgaris, senile xeroderma, senile keratoma, skin damage treatment action due to physical causes, hair growth promotion action, digestive juice secretion promotion action, sweat promotion action Has a function to improve at least one selected from the group consisting of a bowel movement promoting action, and a urination promoting (diuretic) action, and by using this,
Exhibits the effects of preventing and improving skin deterioration, treating atopic dermatitis and preventing the onset and worsening, promoting hair growth and preventing hair loss, improving and preventing eczema, promoting bowel movements and promoting urination. Is done.

【0029】本発明の皮膚外用剤の好ましい投与量は、
疾病の種類や患者の特性によって異なるが、適当量を患
部皮膚や健常皮膚の一部又は全体に適当量一日一回乃至
は数回塗布すればよい。
The preferred dosage of the external preparation for skin of the present invention is
The appropriate amount may be applied once or several times a day to a part or the whole of the affected skin or healthy skin, depending on the kind of the disease and the characteristics of the patient.

【0030】取り分け本発明で注目すべきことは、本発
明の上記一般式(I)で表される化合物又はその生理的
に許容される塩は、経皮投与によって胃酸などの消化液
の分泌が促進される等の効果を有する点であり、経皮投
与でこのような作用を同時に期待しうる物質は未だ知ら
れていない。
In particular, it should be noted that the compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof secretes digestive juices such as gastric acid by transdermal administration. It has the effect of being accelerated and the like, and a substance that can simultaneously expect such an effect by transdermal administration has not been known yet.

【0031】[0031]

【実施例】以下に、本発明の実施例を説明する。尚、表
中の処方の数値は重量部である。
Embodiments of the present invention will be described below. Incidentally, the numerical values of the prescription in the table are parts by weight.

【0032】[0032]

【実施例1〜5】 <配合例>下記表1に示す処方に従って皮膚外用剤(ク
リーム)を作成した。即ち、(イ)、(ロ)、(ハ)の
各成分群をそれぞれ80℃で加熱し、(イ)をよく混練
し、これに(ロ)を加えて希釈し、更にこれに(ハ)を
徐々に加えて乳化し、撹拌冷却して皮膚外用剤を得た。
このものは安全性も高く、下記試験例に示すように優れ
た津液作用を有するので、医薬組成物としても化粧料と
しても有用である。
Examples 1 to 5 <Formulation Examples> Skin external preparations (creams) were prepared according to the formulations shown in Table 1 below. That is, each of the component groups (a), (b) and (c) is heated at 80 ° C., (a) is kneaded well, (b) is added thereto, diluted, and (c) Was gradually added and emulsified, followed by stirring and cooling to obtain a skin external preparation.
It is highly safe and has an excellent essence as shown in the following test examples, and is therefore useful as a pharmaceutical composition and as a cosmetic.

【0033】[0033]

【表1】 [Table 1]

【0034】[0034]

【実施例6〜10】 <配合例>下記表2に示す成分を用いその処方に従っ
て、皮膚外用剤(軟膏)を作成した。即ち、各処方成分
をニーダーに秤込み、よく混練して軟膏を得た。
Examples 6 to 10 <Formulation Examples> A skin external preparation (ointment) was prepared using the components shown in Table 2 below and according to the formulation. That is, each prescription component was weighed into a kneader and kneaded well to obtain an ointment.

【0035】[0035]

【表2】 [Table 2]

【0036】[0036]

【実施例11〜15】 <配合例>下記表3に示す成分を用いてその処方に従っ
て、頭髪用皮膚外用剤(ヘアトニック)を作成した。即
ち、各処方成分を室温で撹拌可溶化し、ヘアトニックを
得た。
Examples 11 to 15 <Formulation Example> An external preparation for hair for hair (hair tonic) was prepared using the components shown in Table 3 below and according to the formulation. That is, each formulation component was stirred and solubilized at room temperature to obtain a hair tonic.

【0037】[0037]

【表3】 [Table 3]

【0038】[0038]

【実施例16〜20】 <配合例>下記表4に示す成分を用いその処方に従っ
て、浴用剤を作成した。即ち、各処方成分をニーダーで
混練し浴用剤を得た。
Examples 16 to 20 <Formulation Examples> Bath ingredients were prepared using the components shown in Table 4 below and according to the formulations. That is, the respective components were kneaded with a kneader to obtain a bath agent.

【0039】[0039]

【表4】 [Table 4]

【0040】[0040]

【実施例21】 <試験例1:美肌改善作用>肌荒れに悩む23〜35歳
のパネラー1群10名が、上記実施例1〜3の皮膚外用
剤(0.02g)を1日朝晩2回ずつ2ヶ月間患部に塗
布し、肌荒れの改善効果を評価した。評価の基準は、非
常に改善した(評点5)〜改善しない(評点0)、とし
た。対照としては、本発明の有効成分である上記一般式
(I)で表される化合物又はその生理的に許容される塩
を水で置換したものを用いた。結果を平均評点として表
5に示す。これより、本発明の皮膚外用剤が肌荒れを改
善する作用を有すること、即ち、美肌作用を有すること
がわかる。これにより、本発明の上記一般式(I)で表
される化合物又はその生理的に許容される塩がこのよう
な作用を有することがわかる。
Example 21 <Test Example 1: Effect of improving skin beautifulness> Ten panelists, a group of 23 to 35 year olds suffering from rough skin, applied the skin external preparations (0.02 g) of Examples 1 to 3 twice daily in the morning and evening. Each was applied to the affected area for two months, and the effect of improving skin roughness was evaluated. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, a compound represented by the above general formula (I), which is an active ingredient of the present invention, or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 5 as average scores. This indicates that the external preparation for skin of the present invention has an effect of improving rough skin, that is, has a skin beautiful effect. This shows that the compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof has such an effect.

【0041】[0041]

【表5】 [Table 5]

【0042】[0042]

【実施例22】 <試験例2:発毛促進作用>C3Hマウス1群5匹の背
部を剃毛し、下記表6に示す検体10mgを生理食塩水
200μlに溶解又は分散させて塗布し、その後の毛の
生え方を観察して発毛促進作用を評価した。対照はベヒ
クルの生理食塩水のみとした。評価の基準は、++(評
点4):対照に比べて著しく早い、+(評点2):対照
に比べて早い、±(評点1):対照に比べてやや早い、
−(評点0):対照に比べて早くない、とした。結果を
平均評点として表6に示す。これより、本発明の皮膚外
用剤の有効成分である上記一般式(I)で表される化合
物又はその生理的に許容される塩は発毛促進作用に優れ
ることがわかる。
Example 22 <Test Example 2: Hair growth promoting action> The back of 5 mice per group of C3H mice was shaved, and 10 mg of a sample shown in Table 6 below was dissolved or dispersed in 200 µl of physiological saline and applied. The hair growth promoting effect was evaluated by observing the hair growth. The control was vehicle saline only. The evaluation criteria are ++ (score 4): significantly earlier than the control, + (score 2): earlier than the control, ± (score 1): slightly earlier than the control,
-(Score 0): Not earlier than control. The results are shown in Table 6 as average scores. This shows that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the external preparation for skin of the present invention, is excellent in hair growth promoting action.

【0043】[0043]

【表6】 [Table 6]

【0044】[0044]

【実施例23】 <試験例3:アトピー性皮膚炎に対する作用>アトピー
性皮膚炎に悩む25〜48歳のパネラー1群10名が、
上記実施例1〜3の皮膚外用剤(0.02g)を1日朝
晩2回ずつ2ヶ月間患部に塗布し、アトピー性皮膚炎の
改善効果を評価した。評価の基準は、非常に改善した
(評点5)〜改善しない(評点0)、とした。対照とし
ては、本発明の上記一般式(I)で表される化合物又は
その生理的に許容される塩を水に置換したものを用い
た。結果を平均評点として表7に示す。これより、本発
明の皮膚外用剤はアトピー性皮膚炎を改善する作用を有
することがわかる。即ち、本発明の上記一般式(I)で
表される化合物又はその生理的に許容される塩がこのよ
うな作用を有することがわかる。
Example 23 <Test Example 3: Effect on atopic dermatitis> A group of 10 panelists aged 25 to 48 years old suffering from atopic dermatitis
The external preparation for skin (0.02 g) of the above Examples 1 to 3 was applied to the affected area twice a day and twice a day for 2 months to evaluate the effect of improving atopic dermatitis. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0). As a control, a compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 7 as average scores. This indicates that the external preparation for skin of the present invention has an effect of improving atopic dermatitis. That is, it is understood that the compound represented by the above general formula (I) of the present invention or a physiologically acceptable salt thereof has such an effect.

【0045】[0045]

【表7】 [Table 7]

【0046】[0046]

【実施例24】 <試験例4:湿疹治療作用>吹き出物に悩む18〜33
歳のパネラー1群10名が、上記実施例1〜3の皮膚外
用剤(0.02g)を1日朝晩2回ずつ2ヶ月間塗布
し、湿疹の改善効果を評価した。評価の基準は、非常に
改善した(評点5)〜改善しない(評点0)、とした。
対照としては、本発明の上記一般式(I)で表される化
合物又はその生理的に許容される塩を水に置換したもの
を用いた。結果を平均評点として表8に示す。これよ
り、本発明の皮膚外用剤の有効成分である上記一般式
(I)で表される化合物又はその生理的に許容される塩
が湿疹を改善する作用を有することがわかる。
Example 24 <Test Example 4: Eczema treatment> 18-33 suffering from breakout
A group of 10-year-old panelists applied the skin external preparations of Examples 1 to 3 (0.02 g) twice a day for 2 months to evaluate the eczema improving effect. The evaluation criteria were very improved (gradation 5) to not improved (gradation 0).
As a control, a compound of the present invention represented by the above general formula (I) or a physiologically acceptable salt thereof was replaced with water. The results are shown in Table 8 as average scores. This indicates that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the external preparation for skin of the present invention, has an effect of improving eczema.

【0047】[0047]

【表8】 [Table 8]

【0048】[0048]

【実施例25】 <試験例5:胃液分泌促進作用>麻酔犬を用いて胃液の
分泌促進を見た。即ち、ペントバルビツールで麻酔した
犬の胃に投与装置付き内視鏡を導入し、検体として表9
に示す本発明の皮膚外用剤の有効成分である上記一般式
(I)で表される化合物又はその生理的に許容される塩
10mgを50%エタノール水溶液200μlに溶解又
は分散させて背部に経皮投与し、その前後の胃液の分泌
を観察して胃液分泌促進作用を評価した。対照は生理食
塩水のみを用いた。評価の基準は、++(評点4):対
照に比べて著しく胃液分泌が増大、+(評点2):対照
に比べて胃液分泌が増大、±(評点1):対照に比べて
やや分泌が増大、−(評点0):分泌が対照に比べて増
大せず、とした。結果を表9に示す。これより、本発明
の有効成分である上記一般式(I)で表される化合物又
はその生理的に許容される塩は胃液分泌促進作用に優れ
ることがわかる。
Example 25 <Test Example 5: Gastric secretion promoting action> The secretion of gastric juice was examined using an anesthetized dog. That is, an endoscope with an administration device was introduced into the stomach of a dog anesthetized with a pentobarbitur, and the specimen was used as a sample.
The compound represented by the general formula (I) or a physiologically acceptable salt thereof (10 mg), which is an active ingredient of the external preparation for skin of the present invention shown in (1), is dissolved or dispersed in 200 μl of a 50% aqueous ethanol solution and transdermally applied to the back After administration, the secretion of gastric juice before and after the administration was observed, and the gastric secretion promoting action was evaluated. As a control, only physiological saline was used. Evaluation criteria were as follows: ++ (score 4): gastric secretion increased significantly compared to control, + (score 2): increased gastric secretion compared to control, ± (score 1): slightly increased compared to control ,-(Score 0): the secretion did not increase compared to the control. Table 9 shows the results. This indicates that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof, which is an active ingredient of the present invention, has excellent gastric secretion promoting action.

【0049】[0049]

【表9】 [Table 9]

【0050】[0050]

【実施例26】 <試験例6:便通・排尿の促進作用>ICRマウスを代
謝ケージで飼育した。投与群は、検体として上記実施例
1〜3の皮膚外用剤を、剃毛した背部皮膚に1g/1日
/1匹、毎日朝夕2回0.5gずつ、7日間塗布して経
皮投与した。最後の投与後24時間の尿と糞の量をモニ
ターした。コントロール群は検体を投与しなかった。各
サンプル1群10匹とした。検体投与群の尿量の総和を
コントロール群の尿量の総和で除した値と検体投与群の
糞量の総和をコントロール群の糞量の総和で除した値と
を表10に示す。これより本発明の上記一般式(I)で
表される化合物又はその生理的に許容される塩は、便通
促進作用及び排尿促進作用(利尿作用)に優れることが
わかる。
Example 26 <Test Example 6: Effect of promoting bowel movement and urination> ICR mice were bred in metabolic cages. In the administration group, the skin external preparations of Examples 1 to 3 were applied to the shaved back skin as a specimen at a rate of 1 g / day / animal, 0.5 g twice daily in the morning and evening, and transdermally administered for 7 days. . The amount of urine and feces 24 hours after the last dose was monitored. The control group received no specimen. Each group consisted of 10 animals. Table 10 shows the value obtained by dividing the total urine volume of the sample administration group by the total urine volume of the control group and the value obtained by dividing the total feces volume of the sample administration group by the total feces volume of the control group. This shows that the compound represented by the above general formula (I) or a physiologically acceptable salt thereof of the present invention is excellent in the bowel movement promoting action and the urination promoting action (diuretic action).

【0051】[0051]

【表10】 [Table 10]

【0052】[0052]

【発明の効果】本発明によれば、美肌作用、アトピー性
皮膚炎治療作用、湿疹で代表される皮膚炎群治療作用、
皮膚真菌症治療作用、疣贅治療作用、肝炎で代表される
色素沈着症治療作用、尋常性乾癬治療症、老人性乾皮
症、老人性角化腫治療作用、物理的原因による皮膚損傷
治療作用、発毛促進作用、消化液分泌促進作用、発汗促
進作用、便通促進作用、及び利尿作用からなる群から選
ばれる津液作用を改善しうる皮膚外用剤を提供すること
ができる。
According to the present invention, a beautiful skin effect, a therapeutic effect on atopic dermatitis, a therapeutic effect on a dermatitis group represented by eczema,
Treatment for dermatomycosis, treatment for warts, treatment for pigmentation such as hepatitis, treatment for psoriasis vulgaris, treatment for senile xeroderma, senile keratoma, treatment for skin damage due to physical causes It is possible to provide a skin external preparation capable of improving a tsukusu action selected from the group consisting of a hair growth promoting action, a digestive juice secretion promoting action, a sweating promoting action, a bowel movement promoting action, and a diuretic action.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI C07C 233/20 C07C 233/20 // C07C 49/35 49/35 219/10 219/10 (72)発明者 安藤 信裕 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 (72)発明者 村松 宜江 神奈川県横浜市神奈川区高島台27番地1 ポーラ化成工業株式会社横浜研究所内 (72)発明者 河合 充夫 神奈川県横浜市戸塚区柏尾町560 ポーラ 化成工業株式会社戸塚研究所内──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification symbol FI C07C 233/20 C07C 233/20 // C07C 49/35 49/35 219/10 219/10 (72) Inventor Nobuhiro Ando Kanagawa 27-1 Takashimadai, Kanagawa-ku, Yokohama-shi, Yokohama Research Laboratory, Polar Research Inc. Mitsuo 560 Kashio-cho, Totsuka-ku, Yokohama-shi, Kanagawa Pref.

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 下記一般式(I)で表される化合物及び
その生理的に許容される塩からなる群から選ばれる1種
又は2種以上を有効成分とする、津液改善用皮膚外用
剤。 【化1】 [式(I)中、R1、R3はそれぞれ独立に低鎖長アルキ
ル基、低鎖長アルキルオキシ基、水酸基又は水素原子を
表し、R2はアシルオキシ基又は水酸基を表し、R4は窒
素原子又は芳香族基を有していてもよいカルボニルアル
ケニル基もしくはアルケニルカルボニル基を表す。]
1. A skin external preparation for improving tsumucus containing one or more active ingredients selected from the group consisting of a compound represented by the following formula (I) and a physiologically acceptable salt thereof. Embedded image [In the formula (I), R 1 and R 3 each independently represent a low-chain alkyl group, a low-chain alkyloxy group, a hydroxyl group or a hydrogen atom, R 2 represents an acyloxy group or a hydroxyl group, and R 4 represents nitrogen. Represents a carbonylalkenyl group or an alkenylcarbonyl group which may have an atom or an aromatic group. ]
【請求項2】 前記一般式(I)で表される化合物が、
下記一般式(II)で表されるカプサイシン、下記一般
式(III)で表されるシナピン、もしくは下記一般式
(IV)で表されるクルクミン又はこれらの低鎖長アシ
ル化物である、請求項1記載の津液改善用皮膚外用剤。 【化2】 【化3】 【化4】
2. The compound represented by the general formula (I)
The capsaicin represented by the following general formula (II), the sinapine represented by the following general formula (III), the curcumin represented by the following general formula (IV), or a low-chain acylated product thereof. The skin external preparation for improving tsukusu according to the above. Embedded image Embedded image Embedded image
【請求項3】 前記一般式(I)で表される化合物及び
その生理的に許容される塩からなる群から選ばれる1種
又は2種以上を0.001〜10重量%含有する、請求
項1又は2記載の津液改善用皮膚外用剤。
3. The composition according to claim 1, which comprises 0.001 to 10% by weight of one or more selected from the group consisting of the compound represented by the general formula (I) and a physiologically acceptable salt thereof. 3. A skin external preparation for improving tsumugi according to 1 or 2.
【請求項4】 化粧料である、請求項1〜3のいずれか
に記載の皮膚外用剤。
4. The external preparation for skin according to claim 1, which is a cosmetic.
【請求項5】 医薬である、請求項1〜3のいずれかに
記載の皮膚外用剤。
5. The external preparation for skin according to claim 1, which is a medicament.
【請求項6】 美肌作用、アトピー性皮膚炎治療作用、
皮膚炎群治療作用、皮膚真菌症治療作用、疣贅治療作
用、色素沈着症治療作用、尋常性乾癬治療症、老人性乾
皮症、老人性角化腫治療作用、皮膚損傷治療作用、発毛
促進作用、消化液分泌促進作用、発汗促進作用、便通促
進作用、及び利尿作用からなる群から選ばれる津液作用
の改善用である、請求項1〜5のいずれかに記載の皮膚
外用剤。
6. A beautiful skin effect, an atopic dermatitis treatment effect,
Dermatitis group treatment, dermatomycosis treatment, wart treatment, pigmentation treatment, psoriasis vulgaris, senile xerosis, senile keratoma treatment, skin damage treatment, hair growth The external preparation for skin according to any one of claims 1 to 5, which is used for improving a tsutsuma action selected from the group consisting of a promoting action, a digestive juice secretion promoting action, a sweating promoting action, a bowel movement promoting action, and a diuretic action.
JP27665896A 1996-10-18 1996-10-18 Skin preparation for improving sputum for external use Pending JPH10120558A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP27665896A JPH10120558A (en) 1996-10-18 1996-10-18 Skin preparation for improving sputum for external use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27665896A JPH10120558A (en) 1996-10-18 1996-10-18 Skin preparation for improving sputum for external use

Publications (1)

Publication Number Publication Date
JPH10120558A true JPH10120558A (en) 1998-05-12

Family

ID=17572526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP27665896A Pending JPH10120558A (en) 1996-10-18 1996-10-18 Skin preparation for improving sputum for external use

Country Status (1)

Country Link
JP (1) JPH10120558A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
JP2004182600A (en) * 2001-10-31 2004-07-02 Daicho Kikaku:Kk Preparation for skin
EP1437117A1 (en) * 2002-12-19 2004-07-14 Cognis France S.A. Use of Sinapic acid and/or its derivatives
US20060204471A1 (en) * 2001-05-29 2006-09-14 L'oreal Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging
JP2007246470A (en) * 2006-03-17 2007-09-27 Daicho Kikaku:Kk New medicine
WO2008132950A1 (en) * 2007-04-13 2008-11-06 Maruishi Pharmaceutical Co., Ltd. External preparation for skin and external preparation for lips
JP2008539253A (en) * 2005-04-25 2008-11-13 ニューロジェシックス, インコーポレイテッド TRPV1 agonist compounds and methods for making and using TRPV1 agonist compounds
JP2012193200A (en) * 2001-10-31 2012-10-11 Daicho Kikaku:Kk Dermatologic preparation

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000201A1 (en) * 1999-06-30 2001-01-04 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
EP1196158A4 (en) * 1999-06-30 2004-05-26 Univ Emory Curcumin and curcuminoid inhibition of angiogenesis
US20060204471A1 (en) * 2001-05-29 2006-09-14 L'oreal Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging
JP2004182600A (en) * 2001-10-31 2004-07-02 Daicho Kikaku:Kk Preparation for skin
JP2014208697A (en) * 2001-10-31 2014-11-06 有限会社大長企画 Agent for the skin of animals
JP2012193200A (en) * 2001-10-31 2012-10-11 Daicho Kikaku:Kk Dermatologic preparation
EP1437117A1 (en) * 2002-12-19 2004-07-14 Cognis France S.A. Use of Sinapic acid and/or its derivatives
US7632519B2 (en) * 2005-04-25 2009-12-15 Neurogesx, Inc. TRPV1 agonist compounds, formulations, prodrugs, methods for using the same
JP2008539253A (en) * 2005-04-25 2008-11-13 ニューロジェシックス, インコーポレイテッド TRPV1 agonist compounds and methods for making and using TRPV1 agonist compounds
JP2007246470A (en) * 2006-03-17 2007-09-27 Daicho Kikaku:Kk New medicine
JPWO2008132950A1 (en) * 2007-04-13 2010-07-22 丸石製薬株式会社 Skin external preparation and lip external preparation
WO2008132950A1 (en) * 2007-04-13 2008-11-06 Maruishi Pharmaceutical Co., Ltd. External preparation for skin and external preparation for lips

Similar Documents

Publication Publication Date Title
JP5922715B2 (en) Composition for controlling and / or stabilizing conditions affecting the skin
JPH10114649A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
KR101135172B1 (en) A composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Phellodendron amurense Rupr, Houttuynia cordata, Paeonia lactiflora Pall, Agrimonia pilosa Ledeb, and Glycyrrhiza uralensis Fisch as an effective ingredient
JP6921440B2 (en) Composition for promoting melanin production containing thistle extract as an active ingredient
JP2003518066A (en) Compositions containing oligosaccharides, especially cosmetic or dermatological compositions, methods for their preparation and methods for cosmetic treatment
Nille et al. Potential implications of Ayurveda in Psoriasis: A clinical case study
JPH07300412A (en) Active oxygen remover and composition containing the same
KR101503158B1 (en) Cosmetic composition for improving skin wrinkle and enhancing elasticity
JPH10120579A (en) Skin preparation for improving sputum for external use
JPH10120558A (en) Skin preparation for improving sputum for external use
JPH10175854A (en) External preparation for skin for improving water (of chinese medicine idea)
JPH10175859A (en) External preparation for skin for improving water (of chinese medicine idea)
KR101586083B1 (en) Cosmetic or pharmaceutical compositions comprising peat extracts
KR101505446B1 (en) Preparation method of 5-aminolevulinic acid and Use of the same
CN102335231B (en) Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof
JPH10120556A (en) Skin preparation for improving sputum for external use
JPH10175868A (en) Water (of chinese medicine idea) improving composition
JPH10120561A (en) Skin preparation for improving sputum for external use
JPH10114665A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
JPH10175852A (en) Water (of chinese medicine idea) improver and composition for oral administration containing the same
JP4049406B2 (en) Tsu fluid improving agent and composition for oral administration containing the same
JPH10114652A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
CN110269926A (en) Middle benefit gas, which is relaxed, warms up composition and its preparation method and application
JPH10175860A (en) Water (of chinese medicine idea) improver and composition for oral administration containing the same
KR102683678B1 (en) Composition for improving skin comprising 2-phloroeckol as an active ingredient

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070626

A977 Report on retrieval

Effective date: 20070628

Free format text: JAPANESE INTERMEDIATE CODE: A971007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071023